A COCKTAIL of drugs targeting breast cancer could double the amount of time patients live without the disease progressing.
Researchers have branded the breakthrough as potentially transformative for those with a common form of advanced, aggressive breast cancer.
Some 325 patients from 28 countries took part in a drug trial. More than half had cancer that had spread to three or more organs, while over 80% had hemotherapy.
A total of 161 patients were given the three-drug therapy, which comprised two targeted drugs palbociclib, a type of cancer growth blocker, and a new drug called inavolisib.
Esta historia es de la edición October 31, 2024 de Daily Mirror UK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 31, 2024 de Daily Mirror UK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar